Hostname: page-component-55f67697df-zpzq9 Total loading time: 0 Render date: 2025-05-11T20:32:52.383Z Has data issue: false hasContentIssue false

Clinical management model for impulse control disorders in Parkinson’s disease

Published online by Cambridge University Press:  29 October 2024

Han Li
Affiliation:
Department of Neurology, The Affiliated Hospital of Qingdao University, Qingdao, China
Yong Yang
Affiliation:
Department of Neurology, The Affiliated Hospital of Qingdao University, Qingdao, China
Liying Yang
Affiliation:
Department of Neurology, The Affiliated Hospital of Qingdao University, Qingdao, China
Anmu Xie*
Affiliation:
Department of Neurology, The Affiliated Hospital of Qingdao University, Qingdao, China Institute of Cerebrovascular Diseases, The Affiliated Hospital of Qingdao University, Qingdao, China
*
Corresponding author: Anmu Xie; Email: [email protected]

Abstract

Over the last decade, we have gained a better understanding of impulse control disorder in Parkinson’s disease (PD-ICD), a medication complication in PD. Researchers were aware of its complexity and took efforts to learn more about its diagnostic and treatment possibilities. Nevertheless, clinical management for it is currently neglected. We conducted a narrative overview of literature published from 2012 to October 2023 on various aspects of clinical management for PD-ICD. A potential “susceptibility-catalytic-stress” model in the development of PD-ICD was proposed and a profile encoding predictors for PD-ICD was created. Based on these predictors, some methods for prediction were recently developed for better prediction, such as the polymorphic dopamine genetic risk score and the clinic-genetic ICD-risk score. A variety of treatment options, including dose reduction of dopamine receptor agonists (DAs), DAs removal, DAs switch, and add-on therapy, are investigated with inconsistent reports. Based on current findings, we developed a clinical management model prototype centered on prevention, consisting of prediction, prevention, follow-up and monitoring, therapy, and recurrence prevention, for clinical reference, and further proposed 4 key clinical management principles, including standardization, prediction centered, persistence, and whole course.

Type
Review
Copyright
© The Author(s), 2024. Published by Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

Ceravolo, R, Frosini, D, Rossi, C, Bonuccelli, U. Impulse control disorders in Parkinson’s disease: definition, epidemiology, risk factors, neurobiology and management. Parkinsonism Relat Disord. Dec 2009;15(Suppl 4):S111S115. doi:10.1016/s1353-8020(09)70847-8.CrossRefGoogle ScholarPubMed
Weintraub, D, Koester, J, Potenza, MN, et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol. May 2010;67(5):589595. doi:10.1001/archneurol.2010.65.CrossRefGoogle ScholarPubMed
Voon, V, Napier, TC, Frank, MJ, et al. Impulse control disorders and levodopa-induced dyskinesias in Parkinson’s disease: an update. Lancet Neurol. 2017;16(3):238250. doi:10.1016/S1474-4422(17)30004-2CrossRefGoogle ScholarPubMed
Lo Monaco, MR, Petracca, M, Weintraub, D, et al. Prevalence of impulsive-compulsive symptoms in elderly Parkinson’s disease patients: a case-control study. J Clin Psychiatry. May/Jun 2018;79(3):17m11612. doi:10.4088/JCP.17m11612.CrossRefGoogle ScholarPubMed
Molde, H, Moussavi, Y, Kopperud, ST, Erga, AH, Hansen, AL, Pallesen, S. Impulse-control disorders in Parkinson’s disease: a meta-analysis and review of case-control studies. Front Neurol. 2018;9(May):330. doi:10.3389/fneur.2018.00330.CrossRefGoogle ScholarPubMed
Dorsey, ER, Sherer, T, Okun, MS, Bloem, BR. The emerging evidence of the Parkinson pandemic. J Parkinsons Dis. 2018;8(s1):S3S8. doi:10.3233/jpd-181474.CrossRefGoogle ScholarPubMed
Evans, AH, Okai, D, Weintraub, D, et al. Scales to assess impulsive and compulsive behaviors in Parkinson’s disease: critique and recommendations. Mov Disord. Jun 2019;34(6):791798. doi:10.1002/mds.27689.CrossRefGoogle ScholarPubMed
Gunduz, A, Çiftçi, T, Erbil, AC, Senoglu, G, Ser, MH, Apaydın, H. Impulse control disorders in Parkinson’s disease: a retrospective analysis of 1824 patients in a 12-year period. Neurol Sci. Aug 15 2023; 45(1):171175. doi:10.1007/s10072-023-07006-1.CrossRefGoogle Scholar
Toś, M, Grażyńska, A, Antoniuk, S, Siuda, J. Impulse control disorders in the Polish population of patients with Parkinson’s disease. Medicina (Kaunas). Aug 16 2023;59(8):1468. doi:10.3390/medicina59081468.CrossRefGoogle ScholarPubMed
Martinez Castrillo, J, Lastras Fernandez-Escandon, C, Domingez Zabaleta, I, Estevez Fraga, C, Sanchez Diez, G, Alonso Canovas, A. Intercultural differences in the frequency of impulsive control disorders in Parkinson’s disease. Movement Disord. 2018;33:S832.Google Scholar
Corvol, JC, Artaud, F, Cormier-Dequaire, F, et al. Longitudinal analysis of impulse control disorders in Parkinson disease. Neurology. 2018;91(3):e189e201. doi:10.1212/WNL.0000000000005816.CrossRefGoogle ScholarPubMed
Parra-Díaz, P, Chico-García, JL, Beltrán-Corbellini, Á, et al. Does the country make a difference in impulse control disorders? A systematic review. Mov Disord Clin Pract. Jan 2021;8(1):2532. doi:10.1002/mdc3.13128.CrossRefGoogle ScholarPubMed
Theis, H, Probst, C, Fernagut, PA-O, van Eimeren, TA-O. Unlucky punches: the vulnerability-stress model for the development of impulse control disorders in Parkinson’s disease. 2021 (2373-8057 (Print)).CrossRefGoogle Scholar
Erga, AH, Alves, G, Tysnes, OB, Pedersen, KF. Impulsive and compulsive behaviors in Parkinson’s disease: impact on quality of and satisfaction with life, and caregiver burden. Parkinsonism Relat Disord. Sep 2020;78:2730. doi:10.1016/j.parkreldis.2020.07.007.CrossRefGoogle ScholarPubMed
Leroi, I, Harbishettar, V, Andrews, M, McDonald, K, Byrne, EJ, Burns, A. Carer burden in apathy and impulse control disorders in Parkinson’s disease. Intl J Geriat Psychiatry. 2012;27(2):160166. doi:10.1002/gps.2704.CrossRefGoogle ScholarPubMed
Paul, B, Paul, G, Singh, G. Gender association of impulse control disorders (ICD-RBS) in patients with Parkinson’s disease and its impact on quality of life. J Neurol Sci. 2019;405:327. doi:10.1016/j.jns.2019.10.1442.CrossRefGoogle Scholar
Nakum, S, Cavanna, AE. The prevalence and clinical characteristics of hypersexuality in patients with Parkinson’s disease following dopaminergic therapy: a systematic literature review. Parkinsonism Relat Disord. Apr 2016;25:1016. doi:10.1016/j.parkreldis.2016.02.017.CrossRefGoogle ScholarPubMed
Hinkle, JT, Perepezko, K, Mills, KA, Pontone, GM. Attentional dysfunction and the punding spectrum in Parkinson’s disease. Parkinsonism Relat Disord. Mar 2021;84:2328. doi:10.1016/j.parkreldis.2021.01.019.CrossRefGoogle ScholarPubMed
Giovannoni, G, O’Sullivan, JD, Turner, K, Manson, AJ, Lees, AJ. Hedonistic homeostatic dysregulation in patients with Parkinson’s disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry. Apr 2000;68(4):423428. doi:10.1136/jnnp.68.4.423.CrossRefGoogle ScholarPubMed
Weintraub, D, Claassen, DO. Impulse control and related disorders in Parkinson’s disease. Int Rev Neurobiol. 2017;133:679717. doi:10.1016/bs.irn.2017.04.006.CrossRefGoogle ScholarPubMed
Rodríguez-Violante, M, Ríos-Solís, Y, Esquivel-Zapata, O, et al. Assessment of therapeutic strategies for management of impulse control disorder in Parkinson’s disease. Arquiv Neuro-Psiquiat. 2021;79(11):989994. doi:10.1590/0004-282X-ANP-2020-0507.CrossRefGoogle ScholarPubMed
Mortazavi, L, Hynes, TJ, Chernoff, CS, et al. D(2/3) agonist during learning potentiates cued risky choice. J Neurosci. Feb 8 2023;43(6):979992. doi:10.1523/jneurosci.1459-22.2022.CrossRefGoogle ScholarPubMed
Barbosa, P, Hapuarachchi, B, Djamshidian, A, et al. Lower nucleus accumbens α-synuclein load and D3 receptor levels in Parkinson’s disease with impulsive compulsive behaviours. Brain. 2019;(1460-2156 (Electronic)). doi:10.1093/brain/awz298.Google ScholarPubMed
Napier, TC, Corvol, JC, Grace, AA, et al. Linking neuroscience with modern concepts of impulse control disorders in Parkinson’s disease. Mov Disord. Feb 2015;30(2):141149. doi:10.1002/mds.26068.CrossRefGoogle ScholarPubMed
Claassen, D, Stark, A, Spears, C, et al. Mesocorticolimbic hemodynamic response in Parkinson’s disease patients with compulsive behaviors. Movement Disord. 2017;32(11):15741583. doi:10.1002/mds.27047.CrossRefGoogle ScholarPubMed
Perez-Lloret, S, Rey, MV, Fabre, N, et al. Prevalence and pharmacological factors associated with impulse-control disorder symptoms in patients with Parkinson disease. Clin Neuropharmacol. Nov–Dec 2012;35(6):261265. doi:10.1097/WNF.0b013e31826e6e6d.CrossRefGoogle ScholarPubMed
Seeman, P. Parkinson’s disease treatment may cause impulse-control disorder via dopamine D3 receptors. Synapse. Apr 2015;69(4):183189. doi:10.1002/syn.21805.CrossRefGoogle ScholarPubMed
Simoni, S, Paoletti, FP, Eusebi, P, et al. Impulse control disorders and levodopa-induced dyskinesias in Parkinson’s disease: pulsatile versus continuous dopaminergic stimulation. J Parkinsons Dis. 2020;10(3):927934. doi:10.3233/jpd-191833.CrossRefGoogle ScholarPubMed
Rizos, A, Sauerbier, A, Antonini, A, et al. A European multicentre survey of impulse control behaviours in Parkinson’s disease patients treated with short- and long-acting dopamine agonists. Eur J Neurol. Aug 2016;23(8):12551261. doi:10.1111/ene.13034.CrossRefGoogle Scholar
Antonini, A, Chaudhuri, KR, Boroojerdi, B, et al. Impulse control disorder related behaviours during long-term rotigotine treatment: a post hoc analysis. Eur J Neurol. Oct 2016;23(10):15561565. doi:10.1111/ene.13078.CrossRefGoogle ScholarPubMed
Nyholm, D. Enteral levodopa/carbidopa gel infusion for the treatment of motor fluctuations and dyskinesias in advanced Parkinson’s disease. Expert Rev Neurother. Oct 2006;6(10):14031411. doi:10.1586/14737175.6.10.1403.CrossRefGoogle ScholarPubMed
Todorova, A, Samuel, M, Brown, RG, Chaudhuri, KR. Infusion therapies and development of impulse control disorders in advanced parkinson disease: clinical experience after 3 years’ follow-up. Clin Neuropharmacol. 2015;38(4):132134. doi:10.1097/WNF.0000000000000091.CrossRefGoogle ScholarPubMed
Tichelaar, JG, Sayalı, C, Helmich, RC, Cools, R. Impulse control disorder in Parkinson’s disease is associated with abnormal frontal value signalling. Brain. Sep 1 2023;146(9):36763689. doi:10.1093/brain/awad162.CrossRefGoogle ScholarPubMed
Tessitore, A, De Micco, R, Giordano, A, et al. Intrinsic brain connectivity predicts impulse control disorders in patients with Parkinson’s disease. Movement Disord. 2017;32(12):17101719. doi:10.1002/mds.27139.CrossRefGoogle ScholarPubMed
Petersen, K, Van Wouwe, N, Stark, A, et al. Ventral striatal network connectivity reflects reward learning and behavior in patients with Parkinson’s disease. Hum Brain Mapp. Jan 2018;39(1):509521. doi:10.1002/hbm.23860.CrossRefGoogle ScholarPubMed
Sparks, H, Riskin-Jones, H, Price, C, et al. Impulsivity relates to relative preservation of mesolimbic connectivity in patients with Parkinson disease. NeuroImage Clinical. 2020;27:102259. doi:10.1016/j.nicl.2020.102259.CrossRefGoogle ScholarPubMed
Garcia-Ruiz, PJ, Martinez Castrillo, JC, Alonso-Canovas, A, et al. Impulse control disorder in patients with Parkinson’s disease under dopamine agonist therapy: a multicentre study. J Neurol Neurosurg Psychiatry. Aug 2014;85(8):840844. doi:10.1136/jnnp-2013-306787.CrossRefGoogle ScholarPubMed
Munro, CA, McCaul, ME, Wong, DF, et al. Sex differences in striatal dopamine release in healthy adults. Biol Psychiatry. May 15 2006;59(10):966974. doi:10.1016/j.biopsych.2006.01.008.CrossRefGoogle ScholarPubMed
Cao, L, Xu, T, Zhao, G, Lv, D, Lu, J, Zhao, G. Risk factors of impulsive-compulsive behaviors in PD patients: a meta-analysis. J Neurol. 2021; 269(3):12981315. doi:10.1007/s00415-021-10724-1.CrossRefGoogle ScholarPubMed
Ihle, J, Artaud, F, Bekadar, S, et al. Parkinson’s disease polygenic risk score is not associated with impulse control disorders: a longitudinal study. Parkinsonism Relat Disord. Jun 2020;75:3033. doi:10.1016/j.parkreldis.2020.03.017.CrossRefGoogle Scholar
Legarda, I, Vives, B, Beltran-Gomila, CA, et al. Impulse control disorder associates with tyrosine hydroxylase 2 gene variants in Parkinson’s disease patients subject to dopaminergic therapy. Movement Disord. 2016;31:S212. doi:10.1002/mds.26688.Google Scholar
Kelly, MJ, Baig, F, Hu, MT, Okai, D. Spectrum of impulse control behaviours in Parkinson’s disease: pathophysiology and management. J Neurol Neurosurg Psychiatry. Jul 2020;91(7):703711. doi:10.1136/jnnp-2019-322453.CrossRefGoogle ScholarPubMed
Cormier-Dequaire, F, Bekadar, S, Anheim, M, et al. Suggestive association between OPRM1 and impulse control disorders in Parkinson’s disease. Mov Disord. Dec 2018;33(12):18781886. doi:10.1002/mds.27519.CrossRefGoogle ScholarPubMed
Kraemmer, J, Smith, K, Weintraub, D, et al. Clinical-genetic model predicts incident impulse control disorders in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2016;87(10):11061111. doi:10.1136/jnnp-2015-312848.CrossRefGoogle ScholarPubMed
Amami, P, De Santis, T, Invernizzi, F, Garavaglia, B, Albanese, A. Impulse control behavior in GBA-mutated parkinsonian patients. J Neurol Sci. Feb 15 2021;421:117291. doi:10.1016/j.jns.2020.117291.CrossRefGoogle ScholarPubMed
Prud’hon, S, Bekadar, S, Rastetter, A, et al. Exome sequencing reveals signal transduction genes involved in impulse control disorders in Parkinson’s disease. Front Neurol. 2020;11:641641. doi:10.3389/fneur.2020.00641.CrossRefGoogle ScholarPubMed
Kara, M, Smith, SXX, Weintraub, Daniel. Incident impulse control disorder symptoms and dopamine transporter imaging in Parkinson disease. J Neurol Neurosurg Psychiatry 2016;87(8):864870. doi:10.1136/jnnp-2015-311827.Google Scholar
Voon, V, Rizos, A, Chakravartty, R, et al. Impulse control disorders in Parkinson’s disease: decreased striatal dopamine transporter levels. J Neurol Neurosurg Psychiatry. Feb 2014;85(2):148152. doi:10.1136/jnnp-2013-305395.CrossRefGoogle ScholarPubMed
Cilia, R, Ko, JH, Cho, SS, et al. Reduced dopamine transporter density in the ventral striatum of patients with Parkinson’s disease and pathological gambling. Neurobiol Dis. Jul 2010;39(1):98104. doi:10.1016/j.nbd.2010.03.013.CrossRefGoogle ScholarPubMed
Vriend, C, Nordbeck, AH, Booij, J, et al. Reduced dopamine transporter binding predates impulse control disorders in Parkinson’s disease. Mov Disord. Jun 2014;29(7):904911. doi:10.1002/mds.25886.CrossRefGoogle ScholarPubMed
en Heuvel, OA, Vriend, C, Nordbeck, AH, et al. Reduced dopamine transporter binding predates impulse control disorders in Parkinson’s disease. Eur Neuropsychopharmacol. 2013;23:S548S549. doi:10.1016/S0924-977X(13)70871-X.CrossRefGoogle Scholar
Navalpotro-Gomez, I, Dacosta-Aguayo, R, Molinet-Dronda, F, et al. Nigrostriatal dopamine transporter availability, and its metabolic and clinical correlates in Parkinson’s disease patients with impulse control disorders. Eur J Nucl Med Mol Imaging. 2019;46(10):20652076. doi:10.1007/s00259-019-04396-3.CrossRefGoogle ScholarPubMed
Erga, AH, Dalen, I, Ushakova, A, et al. Dopaminergic and opioid pathways associated with impulse control disorders in Parkinson’s disease. Front Neurol. 2018;9:109. doi:10.3389/fneur.2018.00109.CrossRefGoogle ScholarPubMed
Nandam, LS, Hester, R, Wagner, J, et al. Dopamine D₂ receptor modulation of human response inhibition and error awareness. J Cogn Neurosci. Apr 2013;25(4):649656. doi:10.1162/jocn_a_00327.CrossRefGoogle ScholarPubMed
MacDonald, HJ, Stinear, CM, Ren, A, et al. Dopamine gene profiling to predict impulse control and effects of dopamine agonist ropinirole. J Cogn Neurosci. Jul 2016;28(7):909919. doi:10.1162/jocn_a_00946.CrossRefGoogle ScholarPubMed
Hall, A, Weaver, SR, Compton, LJ, Byblow, WD, Jenkinson, N, MacDonald, HJ. Dopamine genetic risk score predicts impulse control behaviors in Parkinson’s disease. Clin Park Relat Disord. 2021;5:100113. doi:10.1016/j.prdoa.2021.100113.Google ScholarPubMed
Hall, A, Weightman, M, Jenkinson, N, MacDonald, HJ. Performance on the balloon analogue risk task and anticipatory response inhibition task is associated with severity of impulse control behaviours in people with Parkinson’s disease. Exp Brain Res. Apr 2023;241(4):11591172. doi:10.1007/s00221-023-06584-y.CrossRefGoogle ScholarPubMed
Poletti, M, Logi, C, Lucetti, C, et al. A single-center, cross-sectional prevalence study of impulse control disorders in Parkinson disease: association with dopaminergic drugs. J Clin Psychopharmacol. Oct 2013;33(5):691694.CrossRefGoogle ScholarPubMed
Kim, J, Kim, M, Kwon, DY, et al. Clinical characteristics of impulse control and repetitive behavior disorders in Parkinson’s disease. J Neurol. Feb 2013;260(2):429437. doi:10.1007/s00415-012-6645-9.CrossRefGoogle ScholarPubMed
Callesen, MB, Weintraub, D, Damholdt, MF, Møller, A. Impulsive and compulsive behaviors among Danish patients with Parkinson’s disease: prevalence, depression, and personality. Parkinsonism Relat Disord. Jan 2014;20(1):2226. doi:10.1016/j.parkreldis.2013.09.006.CrossRefGoogle ScholarPubMed
Jesús, S, Labrador-Espinosa, MA, Adarmes, AD, et al. Non-motor symptom burden in patients with Parkinson’s disease with impulse control disorders and compulsive behaviours: results from the COPPADIS cohort. Sci Rep. Oct 9 2020;10(1):16893. doi:10.1038/s41598-020-73756-z.CrossRefGoogle ScholarPubMed
Dragogna, F, Mauri, MC, Marotta, G, Armao, FT, Brambilla, P, Altamura, AC. Brain metabolism in substance-induced psychosis and schizophrenia: a preliminary PET study. Neuropsychobiology. 2014;70(4):195202. doi:10.1159/000366485.CrossRefGoogle ScholarPubMed
Liu, B, Luo, W, Mo, Y, Wei, C, Tao, R, Han, M. Meta-analysis of related factors of impulse control disorders in patients with Parkinson’s disease. Neurosci Lett. Aug 10 2019;707:134313. doi:10.1016/j.neulet.2019.134313.CrossRefGoogle ScholarPubMed
Bastiaens, J, Dorfman, BJ, Christos, PJ, Nirenberg, MJ. Prospective cohort study of impulse control disorders in Parkinson’s disease. Article. Movement Disord. 2013;28(3):327333. doi:10.1002/mds.25291.CrossRefGoogle ScholarPubMed
Antonini, A, Barone, P, Bonuccelli, U, Annoni, K, Asgharnejad, M, Stanzione, P. ICARUS study: prevalence and clinical features of impulse control disorders in Parkinson’s disease. J Neurol Neurosurg Psychiatry. Apr 2017;88(4):317324. doi:10.1136/jnnp-2016-315277.CrossRefGoogle ScholarPubMed
Baig, F, Kelly, MJ, Lawton, MA, et al. Impulse control disorders in Parkinson disease and RBD: A longitudinal study of severity. Neurology. Aug 13 2019;93(7):e675e687. doi:10.1212/wnl.0000000000007942.CrossRefGoogle ScholarPubMed
Voon, V, Sohr, M, Lang, AE, et al. Impulse control disorders in Parkinson disease: a multicenter case--control study. Ann Neurol. Jun 2011;69(6):986–696. doi:10.1002/ana.22356.CrossRefGoogle ScholarPubMed
Voon, V, Mehta, AR, Hallett, M. Impulse control disorders in Parkinson’s disease: recent advances. Curr Opin Neurol. Aug 2011;24(4):324330. doi:10.1097/WCO.0b013e3283489687.CrossRefGoogle ScholarPubMed
Kenangil, G, Ozekmekçi, S, Sohtaoglu, M, Erginöz, E. Compulsive behaviors in patients with Parkinson’s disease. Neurologist. May 2010;16(3):192195. doi:10.1097/NRL.0b013e31819f952b.CrossRefGoogle ScholarPubMed
Grall-Bronnec, M, Victorri-Vigneau, C, Donnio, Y, et al. Dopamine agonists and impulse control disorders: a complex association. Drug Saf. Jan 2018;41(1):1975. doi:10.1007/s40264-017-0590-6.CrossRefGoogle ScholarPubMed
Moore, TJ, Glenmullen, J, Mattison, DR. Reports of pathological gambling, hypersexuality, and compulsive shopping associated with dopamine receptor agonist drugs. JAMA Intern Med. Dec 2014;174(12):19301933. doi:10.1001/jamainternmed.2014.5262.CrossRefGoogle ScholarPubMed
Leplow, B, Renftle, D, Thomas, M, et al. Characteristics of behavioural addiction in Parkinson’s disease patients with self-reported impulse control disorder and controls matched for levodopa equivalent dose: a matched case-control study. J Neural Transm (Vienna). Feb 2023;130(2):125133. doi:10.1007/s00702-023-02588-8.CrossRefGoogle Scholar
Goerlich-Dobre, KS, Probst, C, Winter, L, et al. Alexithymia-an independent risk factor for impulsive-compulsive disorders in Parkinson’s disease. Mov Disord. Feb 2014;29(2):214220. doi:10.1002/mds.25679.CrossRefGoogle ScholarPubMed
Lee, JY, Seo, SH, Kim, YK, et al. Extrastriatal dopaminergic changes in Parkinson’s disease patients with impulse control disorders. J Neurol Neurosurg Psychiatry. 2014;85(1):2330. doi:10.1136/jnnp-2013-305549.CrossRefGoogle ScholarPubMed
Jaakkola, E, Huovinen, A, Kaasinen, V, Joutsa, J. No change in prevalence of impulse control disorder behaviors in Parkinson’s disease during the last decade. Mov Disord. Feb 2021;36(2):521523. doi:10.1002/mds.28400.CrossRefGoogle ScholarPubMed
Ramírez Gómez, CC, Serrano Dueñas, M, Bernal, O, et al. A multicenter comparative study of impulse control disorder in Latin American patients with Parkinson disease. Clin Neuropharmacol. Mar/Apr 2017;40(2):5155. doi:10.1097/wnf.0000000000000202.CrossRefGoogle ScholarPubMed
Biundo, R, Weis, L, Abbruzzese, G, et al. Impulse control disorders in advanced Parkinson’s disease with dyskinesia: The ALTHEA study. Mov Disord. Nov 2017;32(11):15571565. doi:10.1002/mds.27181.CrossRefGoogle ScholarPubMed
Nikitina, M, Alifirova, V, Nurzhanova, K, Bragina, E, Zhukova, N, Brazovskaya, N. The influence of impulse-compulsive disorders on depression in patients with Parkinson’s disease. Eur J Neurol. 2021;28(Suppl 1):788. doi:10.1111/ene.14975.Google Scholar
Waskowiak, P, Koppelmans, V, Ruitenberg, MFL. Trait anxiety as a risk factor for impulse control disorders in de novo Parkinson’s disease. J Parkinsons Dis. Dec 7 2021;12(2):689697. doi:10.3233/jpd-212959.CrossRefGoogle Scholar
Scott, BM, Eisinger, RS, Burns, MR, et al. Co-occurrence of apathy and impulse control disorders in Parkinson disease. Neurology. Nov 17 2020;95(20):e2769e2780. doi:10.1212/wnl.0000000000010965.CrossRefGoogle ScholarPubMed
Siri, C, Cilia, R, Reali, E, et al. Long-term cognitive follow-up of Parkinson’s disease patients with impulse control disorders. Movement Disord. 2015;30(5):696704. doi:10.1002/mds.26160.CrossRefGoogle ScholarPubMed
Marín-Lahoz, J, Sampedro, F, Horta-Barba, A, et al. Preservation of brain metabolism in recently diagnosed Parkinson’s impulse control disorders. Eur J Nucl Med Mol Imaging. 2020;47(9):21652174. doi:10.1007/s00259-019-04664-2.CrossRefGoogle ScholarPubMed
Figorilli, M, Congiu, P, Lecca, R, Gioi, G, Frau, R, Puligheddu, M. Sleep in Parkinson’s disease with impulse control disorder. Curr Neurol Neurosci Rep. 2018;18(10):68. doi:10.1007/s11910-018-0875-x.CrossRefGoogle ScholarPubMed
Fantini, ML, Fedler, J, Pereira, B, Weintraub, D, Marques, AR, Durif, F. Is rapid eye movement sleep behavior disorder a risk factor for impulse control disorder in parkinson disease? Ann Neuro. 2020;88(4):759770. doi:10.1002/ana.25798.CrossRefGoogle ScholarPubMed
Otaiku, A. Impulse control disorders in idiopathic REM sleep behaviour disorder and drug-naive Parkinson’s disease. Movement Disord. 2021;36(Suppl 1):S430S431. doi:10.1002/mds.28794.Google Scholar
Markovic, V, Stankovic, I, Petrovic, I, et al. Impulse control disorder in early Parkinson’s disease: Follow-up study. Movement Disord. 2016;31:S489. doi:10.1002/mds.26688.Google Scholar
Weintraub, D, Posavi, M, Fontanillas, P, et al. Genetic prediction of impulse control disorders in Parkinson’s disease. Ann Clin Transl Neurol. Jul 2022;9(7):936949. doi:10.1002/acn3.51569.CrossRefGoogle ScholarPubMed
Marín-Lahoz, J, Pagonabarraga, J, Martinez-Horta, S, et al. Parkinson’s disease: impulsivity does not cause impulse control disorders but boosts their severity. Front Psychiatry. 2018;9:465. doi:10.3389/fpsyt.2018.00465.CrossRefGoogle Scholar
Du, S, Huang, Y, Ma, Y, et al. The mediating effects of depression, anxiety, and rapid eye movement sleep behavior disorder on the association between dopaminergic replacement therapy and impulse control disorders in Parkinson’s disease. Neurol Sci. Feb 2023;44(2):557564. doi:10.1007/s10072-022-06443-8.CrossRefGoogle ScholarPubMed
Morgante, F, Fasano, A, Ginevrino, M, et al. Impulsive-compulsive behaviors in Parkin-associated Parkinson’s disease: a case-control study. Parkinsonism Relat Disord. 2016;22:e26e27. doi:10.1016/j.parkreldis.2015.10.561.CrossRefGoogle Scholar
Paz-Alonso, P, Navalpotro-Gomez, I, Boddy, P, et al. Functional inhibitory control dynamics in impulse control disorders in Parkinson’s disease. Movement Disord. 2020;35(2):316325. doi:10.1002/mds.27885.CrossRefGoogle ScholarPubMed
Yamanishi, Y, Ando, R, Yamasaki, C, et al. An association between impulse control disorders and dopamine agonists in Japanese patients with Parkinson’s disease. Movement Disord. 2017;32:52. doi:10.1002/mds.27087.Google Scholar
Baumann-Vogel, H, Valko, PO, Eisele, G, Baumann, CR. Impulse control disorders in Parkinson’s disease: don’t set your mind at rest by self-assessments. Eur J Neurol. Apr 2015;22(4):603609. doi:10.1111/ene.12646.CrossRefGoogle ScholarPubMed
Lee, Jee-Young, J, B, Koh, Seong-Beom, Yoon, Won Tae, Lee, Ho-Won, Kwon, Oh Dae, Kim, Jae Woo, Ki, . Behavioural and trait changes in parkinsonian patients with impulse control disorder after switching from dopamine agonist to levodopa therapy: results of REIN-PD trial. J Neurology, Neurosurg Psychiatry. 2018;90(1):3037. doi:10.1136/jnnp-2018-318942.CrossRefGoogle ScholarPubMed
Mamikonyan, E, Siderowf, AD, Duda, JE, et al. Long-term follow-up of impulse control disorders in Parkinson’s disease. Mov Disord. Jan 2008;23(1):7580. doi:10.1002/mds.21770.CrossRefGoogle ScholarPubMed
Choi, JH, Lee, JY, Jeon, B, et al. Neuropsychiatric traits associated with refractory impulse control disorder in Parkinson’s disease. Neurodegenerative Diseases. 2020;19(5–6):171177. doi:10.1159/000507447.CrossRefGoogle Scholar
Okai, D, Samuel, M, Askey-Jones, S, David, AS, Brown, RG. Impulse control disorders and dopamine dysregulation in Parkinson’s disease: a broader conceptual framework. Eur J Neurol. Dec 2011;18(12):13791383. doi:10.1111/j.1468-1331.2011.03432.x.CrossRefGoogle ScholarPubMed
Nirenberg, MJ. Treatment of impulse control disorders and dopamine agonist withdrawal syndrome in Parkinson’s disease. Current Clinical Neurology. 2019:121123. vol. (Nirenberg M.J., [email protected]) The New York Stem Cell Foundation Research Institute, New York, NY, United States.CrossRefGoogle Scholar
Kwan, C, Kolivakis, T, Huot, P. Dopamine agonist withdrawal syndrome and suicidality in Parkinson’s disease. Can J Neurol Sci. Sep 2023;50(5):779780. doi:10.1017/cjn.2022.272.CrossRefGoogle ScholarPubMed
Evans, AH, Pavese, N, Lawrence, AD, et al. Compulsive drug use linked to sensitized ventral striatal dopamine transmission. Ann Neurol. May 2006;59(5):852858. doi:10.1002/ana.20822.CrossRefGoogle ScholarPubMed
Volkmann, J, Albanese, A, Antonini, A, et al. Selecting deep brain stimulation or infusion therapies in advanced Parkinson’s disease: an evidence-based review. J Neurol. Nov 2013;260(11):27012714. doi:10.1007/s00415-012-6798-6.CrossRefGoogle ScholarPubMed
Kashihara, K, Kitayama, M. Impulse control disorders could be accompanied by hypomanic state under intestinal levodopa infusion. Movement Disord. 2018;33:S176.Google Scholar
Gatto, EM, Aldinio, V. Impulse control disorders in Parkinson’s disease. A brief and comprehensive review. Front Neurol. 2019;10:351. doi:10.3389/fneur.2019.00351.CrossRefGoogle ScholarPubMed
Dalley, JW, Robbins, TW. Fractionating impulsivity: neuropsychiatric implications. Nat Rev Neurosci. Feb 17 2017;18(3):158171. doi:10.1038/nrn.2017.8.CrossRefGoogle Scholar
Thomas, A, Bonanni, L, Gambi, F, Di Iorio, A, Onofrj, M. Pathological gambling in Parkinson disease is reduced by amantadine. Ann Neurol. Sep 2010;68(3):400404. doi:10.1002/ana.22029.CrossRefGoogle ScholarPubMed
Cera, N, Bifolchetti, S, Martinotti, G, et al. Amantadine and cognitive flexibility: decision making in Parkinson’s patients with severe pathological gambling and other impulse control disorders. Neuropsychiatr Dis Treat. 2014;10:10931101. doi:10.2147/ndt.S54423.CrossRefGoogle ScholarPubMed
Binck, S, Pauly, C, Kolber, P, et al. Frequency of impulse control disorder in Parkinson’s disease: Insights from the Luxembourg cohort. Eur J Neurol. 2019;26:148. doi:10.1111/ene.14018.Google Scholar
Carrarini, C, Russo, M, Barbone, F, et al. High dose off-label safinamide treatment in young onset Parkinson’s disease patients. Movement Disorder. 2019;34:S33.Google Scholar
Kim, SW, Grant, Je, Adson, DE, Shin, YC. Double-blind naltrexone and placebo comparison study in the treatment of pathological gambling. 2001;49(11):914921. doi:10.1016/S0006-3223(01)01079-4.CrossRefGoogle Scholar
Papay, K, Xie, SX, Stern, M, et al. Naltrexone for impulse control disorders in Parkinson disease: a placebo-controlled study. Neurology. 2014;83(9):826833. doi:10.1212/WNL.0000000000000729.CrossRefGoogle ScholarPubMed
Kraus, SA-O, Etuk, R, Potenza, MA-O. Current pharmacotherapy for gambling disorder: a systematic review. Expert opinion on pharmacotherapy. 2019;21(3):287296. doi:10.1080/14656566.2019.1702969.CrossRefGoogle Scholar
Liang, J, Groves, M, Shanker, VL. Clozapine treatment for impulse control disorders in Parkinson’s disease patients: a case series. 2015;2(3):283285. doi:10.1002/mdc3.12167.CrossRefGoogle Scholar
Zimmerman, M, Breen, Rb, Posternak, MA, Posternak, MA. An open-label study of citalopram in the treatment of pathological gambling. 2002;63(1):4448. doi:10.4088/jcp.v63n0109.CrossRefGoogle Scholar
Hicks, CW, Pandya, Mm Fau-Itin, I, Itin, I Fau-Fernandez, HH, Fernandez, HH. Valproate for the treatment of medication-induced impulse-control disorders in three patients with Parkinson’s disease. 2011;17(5):379381. doi:10.1016/j.parkreldis.2011.03.003.CrossRefGoogle Scholar
Albani, G, Veneziano, G, Spensieri, V, Peppe, A, Grassi, G. Therapeutical purposes for dopaminergic dysregulation syndrome and impulsive behavior in Parkinson’s disease. J Behav Addict. 2019;8:126.Google Scholar
Mata-Marín, D, Pineda-Pardo, J, Michiels, M, et al. A circuit-based approach to modulate hypersexuality in Parkinson’s disease. Psychiatry Clin Neurosci. Apr 2023;77(4):223232. doi:10.1111/pcn.13523.CrossRefGoogle ScholarPubMed
Garlovsky, JK, Simpson, J, Grünewald, RA, Overton, PG. Impulse control disorders in Parkinson’s disease: predominant role of psychological determinants. Psychol Health. 2016;31(12):13911414.CrossRefGoogle ScholarPubMed
Okai, D, Askey-Jones, S, Samuel, M, et al. Trial of CBT for impulse control behaviors affecting Parkinson patients and their caregivers. Neurology. Feb 26 2013;80(9):792–729. doi:10.1212/WNL.0b013e3182840678.CrossRefGoogle ScholarPubMed
Eisinger, R, Cagle, J, Alcantara, J, et al. Distinct roles of the human subthalamic nucleus and dorsal pallidum in Parkinson’s disease impulsivity. Biol Psychiatry. 2022;91(4):370379. doi:10.1016/j.biopsych.2021.03.002.CrossRefGoogle ScholarPubMed
Kim, M, Baybayan, S, Moussawi, K, Mills, K. Deep brain stimulation of anterior globus pallidus internus reduces impulsivity in Parkinson’s disease. Movement Disorder. 2021;36(Suppl 1):S546S547. doi:10.1002/mds.28794.Google Scholar
Kim, A, Kim, YE, Kim, HJ, et al. A 7-year observation of the effect of subthalamic deep brain stimulation on impulse control disorder in patients with Parkinson’s disease. Parkinsonism Relat Disord. 2018;56:38. doi:10.1016/j.parkreldis.2018.07.010.CrossRefGoogle ScholarPubMed
Lhommée, E, Klinger, H, Thobois, S, et al. Subthalamic stimulation in Parkinson’s disease: restoring the balance of motivated behaviours. Brain. May 2012;135(Pt 5):14631477. doi:10.1093/brain/aws078.CrossRefGoogle ScholarPubMed
Frederic, PG, Camille, P, Nicolas, J, Abbas, S, Maria, F, Michel, P. Impulse control disorders after STN DBS for Parkinson’s disease. Movement Disord. 2016;31:S122S123. doi:10.1002/mds.26688.Google Scholar
Rossi, PJ, De Jesus, S, Hess, CW, et al. Measures of impulsivity in Parkinson’s disease decrease after DBS in the setting of stable dopamine therapy. Parkinsonism Relat Disord. Nov 2017;44:1317. doi:10.1016/j.parkreldis.2017.08.006.CrossRefGoogle ScholarPubMed
Amami, P, Dekker, I, Piacentini, S, et al. Impulse control behaviours in patients with Parkinson’s disease after subthalamic deep brain stimulation: de novo cases and 3-year follow-up. J Neurol Neurosurg Psychiatry. May 2015;86(5):562564. doi:10.1136/jnnp-2013-307214.CrossRefGoogle ScholarPubMed
Kasemsuk, C, Oyama, G, Hattori, N. Management of impulse control disorders with deep brain stimulation: a double-edged sword. J Neurol Sci. Mar 15 2017;374:6368. doi:10.1016/j.jns.2017.01.019.CrossRefGoogle ScholarPubMed
Lhommée, E, Boyer, F, Wack, M, et al. Personality, dopamine, and Parkinson’s disease: Insights from subthalamic stimulation. Movement Disord. 2017;32(8):11911200. doi:10.1002/mds.27065.CrossRefGoogle ScholarPubMed
Santin, MDN, Voulleminot, P, Vrillon, A, et al. Impact of subthalamic deep brain stimulation on impulse control disorders in Parkinson’s disease: a prospective study. Movement Disord. 2021;36(3):750757. doi:10.1002/mds.28320.CrossRefGoogle ScholarPubMed
Kon, T, Ueno, T, Haga, R, Tomiyama, M. The factors associated with impulse control behaviors in Parkinson’s disease: a 2-year longitudinal retrospective cohort study. Brain Behav. Aug 2018;8(8):e01036. doi:10.1002/brb3.1036.CrossRefGoogle ScholarPubMed
Mosley, PE, Smith, D, Coyne, T, Silburn, P, Breakspear, M, Perry, A. The site of stimulation moderates neuropsychiatric symptoms after subthalamic deep brain stimulation for Parkinson’s disease. Neuroimage Clin. 2018;18:9961006. doi:10.1016/j.nicl.2018.03.009.CrossRefGoogle ScholarPubMed
Kardous, R, Joly, H, Giordana, B, et al. Functional and dysfunctional impulsivities changes after subthalamic nucleus-deep brain stimulation in Parkinson disease. Neurochirurgie. 2021;67(5):420426. doi:10.1016/j.neuchi.2021.03.013.CrossRefGoogle ScholarPubMed
Rodriguez-Oroz, MC, López-Azcárate, J, Garcia-Garcia, D, et al. Involvement of the subthalamic nucleus in impulse control disorders associated with Parkinson’s disease. Brain. Jan 2011;134(Pt 1):3649. doi:10.1093/brain/awq301.CrossRefGoogle ScholarPubMed
Castrioto, A, Lhommée, E, Moro, E, Krack, P. Mood and behavioural effects of subthalamic stimulation in Parkinson’s disease. Lancet Neurol. Mar 2014;13(3):287305. doi:10.1016/s1474-4422(13)70294-1.CrossRefGoogle ScholarPubMed
Fusaroli, M, Raschi, E, Contin, M, et al. Impulsive conditions in Parkinson’s disease: a pharmacosurveillance-supported list. Parkinsonism Relat Disord. Sep 2021;90:7983. doi:10.1016/j.parkreldis.2021.08.006.CrossRefGoogle ScholarPubMed
Supplementary material: File

Li et al. supplementary material

Li et al. supplementary material
Download Li et al. supplementary material(File)
File 265.5 KB